[1] 国家心血管病中心. 中国心血管健康与疾病报告 2021[M]. 北京:科学出版社, 2022.
[2] Arnett DK, Blumenthal RS, Albert MA, et al.2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2019,140(11):e596-e646.
[3] Ralston J, Nugent R.Toward a broader response to cardiometabolic disease[J]. Nat Med, 2019, 25(11): 1644-1646.
[4] 王增武,刘静,李建军,等. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271.
[5] Nabel E G,Braunwald E.A tale of coronary artery diseaseand myocardial infarction[J]. N Engl J Med,2012,366(1):54-63.
[6] Tarone R E, Mclaughlin J K.Coronary arteries,myocardial infarction,and history[J]. N Engl J Med,2012,366(13):1259.
[7] Song PK, Man QQ, Li H, et al.Trends in lipids level anddyslipidemia among Chinese adults, 2002-2015[J]. Biomed EnvironSci, 2019, 32(8): 559-570.
[8] 国家卫生健康委员会疾病预防控制局. 中国居民营养与慢性病状况报告2020[M]. 北京: 人民卫生出版社, 2020.
[9] Pan L, Yang Z, Wu Y, et al.The prevalence, awareness, treatment andcontrol of dyslipidemia among adults in China[J]. Atherosclerosis,2016,248:2-9.
[10] Lu Y, Zhang H, Lu J, et al.Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China[J]. JAMA Netw Open, 2021, 4(9): e2127573.
[11] Saxon DR, Reiter-Brennan C, Blaha MJ,etal. Cardiometabolic Medicine: Development of a New Subspecialty. J Clin Endocrinol Metab, 2020,105(7).
[12] 周乐群,朱丹,唐熠达. 关于心血管代谢医学的历史、现状与方向[J]. 中华医学杂志,2022,102(30):2389-2393.
[13] 杨林承,张瑞涛,徐玲,等. “一站式”综合管理多重代谢紊乱患者代谢指标治疗效果的变化分析[J]. 中华医学杂志,2022,102(46):3698-3703.
[14] 顾东风,翁建平,鲁向锋. 中国健康生活方式预防心血管代谢疾病指南[J]. 中国循环杂志, 2020, 35(03): 209-230.
[15] PiercyKL, TroianoRP, BallardRM,et al.The physical activity guidelines for Americans[J].JAMA, 2018, 320(19): 2020-2028. |
